These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. McPhail GL; Clancy JP Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952 [TBL] [Abstract][Full Text] [Related]
23. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR. Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810 [TBL] [Abstract][Full Text] [Related]
24. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
25. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001 [TBL] [Abstract][Full Text] [Related]
26. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis. Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070 [TBL] [Abstract][Full Text] [Related]
27. Lack of correlation between CFTR expression, CFTR Cl- currents, amiloride-sensitive Na+ conductance, and cystic fibrosis phenotype. Beck S; Kühr J; Schütz VV; Seydewitz HH; Brandis M; Greger R; Kunzelmann K Pediatr Pulmonol; 1999 Apr; 27(4):251-9. PubMed ID: 10230924 [TBL] [Abstract][Full Text] [Related]
28. Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis. Yeh JT; Yu YC; Hwang TC J Physiol; 2019 Jan; 597(2):543-560. PubMed ID: 30408177 [TBL] [Abstract][Full Text] [Related]
29. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related]
30. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients. Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Cholon DM; Esther CR; Gentzsch M Expert Rev Precis Med Drug Dev; 2016; 1(3):235-243. PubMed ID: 27482545 [TBL] [Abstract][Full Text] [Related]
33. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T. Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453 [TBL] [Abstract][Full Text] [Related]
34. The proteome speciation of an immortalized cystic fibrosis cell line: New perspectives on the pathophysiology of the disease. Puglia M; Landi C; Gagliardi A; Breslin L; Armini A; Brunetti J; Pini A; Bianchi L; Bini L J Proteomics; 2018 Jan; 170():28-42. PubMed ID: 28970102 [TBL] [Abstract][Full Text] [Related]
35. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl Wang Y; Cai Z; Gosling M; Sheppard DN Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L846-L857. PubMed ID: 30136610 [TBL] [Abstract][Full Text] [Related]
36. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report. Johns JD; Rowe SM BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159 [TBL] [Abstract][Full Text] [Related]
37. Augmentation of S-Nitrosoglutathione Controls Cigarette Smoke-Induced Inflammatory-Oxidative Stress and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis by Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function. Bodas M; Silverberg D; Walworth K; Brucia K; Vij N Antioxid Redox Signal; 2017 Sep; 27(7):433-451. PubMed ID: 28006950 [TBL] [Abstract][Full Text] [Related]
38. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Bell SC; De Boeck K; Amaral MD Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877 [TBL] [Abstract][Full Text] [Related]
39. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway. Eidelman O; Srivastava M; Zhang J; Leighton X; Murtie J; Jozwik C; Jacobson K; Weinstein DL; Metcalf EL; Pollard HB Mol Med; 2001 Aug; 7(8):523-34. PubMed ID: 11591888 [TBL] [Abstract][Full Text] [Related]
40. Dendrimer-based selective autophagy-induction rescues ΔF508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis. Brockman SM; Bodas M; Silverberg D; Sharma A; Vij N PLoS One; 2017; 12(9):e0184793. PubMed ID: 28902888 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]